Clinical Trials Logo

Clinical Trial Summary

Oxidative stress is involved in the pathophysiology of diabetic nephropathy. The superoxide-generating nicotinamide adenine dinucleotide phosphate-oxidase 2 (NOX2, encoded by the CYBB gene) and the antioxidant enzyme glutathione peroxidase 4 (GPX4) play opposing roles in the balance of cellular redox status. In the present study, we investigated associations of single nucleotide polymorphisms (SNPs) in the regulatory regions of CYBB and GPX4 with kidney disease in patients with type 1 diabetes.


Clinical Trial Description

In the present study, three cohorts of type 1 diabetic patients (one Brazilian and two French/Belgium cohorts) were studied for the association with diabetic nephropathy (DN) with a total of 1396 patients. The patients were classified according to the urinary albumin-to-creatinine ratio (ACR) or urinary albumin excretion rate (UAER) in absence of nephropathy, defined as ACR <30 mg/g or UAER < 20 µg/min or < 20 mg/L and plasma creatinine <1.7 mg/dL; incipient nephropathy, defined as persistent microalbuminuria (ACR 30 - 300 mg/g of creatinine or UAER 20 - 200 µg/min or 20 - 200 mg/L) and plasma creatinine <1.7 mg/dL; established diabetic nephropathy, defined as past or present macroalbuminuria (ACR >300 mg/g of creatinine or UAER >200 µg/min or > 200 mg/L) and plasma creatinine <1.7 mg/dL; advanced diabetic nephropathy, defined as past or present macroalbuminuria, plasma creatinine >1.7 mg/dL and any renal replacement therapy. Genotyping of polymorphisms was performed by Real Time PCR using fluorescent-labelled probes. ;


Study Design

Observational Model: Case-Only, Time Perspective: Cross-Sectional


Related Conditions & MeSH terms


NCT number NCT01810822
Study type Observational
Source University of Sao Paulo General Hospital
Contact
Status Completed
Phase N/A
Start date May 1994
Completion date October 2012

See also
  Status Clinical Trial Phase
Recruiting NCT04562025 - Clinical Research of UC-MSCs in the Treatment of Diabetic Nephropathy N/A
Not yet recruiting NCT03658317 - Renal Resisitive Index as an Indicator of the Progression of Diabetic Nephropathy N/A
Recruiting NCT02501772 - The Evaluation of Effect of Sanyinjiao (SP6) Acupressure on Early Diabetic Nephropathy N/A
Completed NCT02829177 - Microalbuminuria and Allopurinol in Type 1 Diabetes Phase 4
Completed NCT02276196 - Effect of LIXIsenatide on the Renal System Phase 4
Completed NCT02251067 - Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients Phase 2
Completed NCT01440257 - A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria Phase 2
Active, not recruiting NCT01273675 - An Investigation on the Effect of Candesartan on Early Diabetic Nephropathy N/A
Terminated NCT01129557 - Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease Phase 4
Completed NCT00317954 - Spironolactone in Diabetic Nephropathy Phase 4
Active, not recruiting NCT02237352 - Mechanisms of Diabetic Nephropathy in Ecuador
Not yet recruiting NCT05061459 - The Expression of circANKRD36 as a New Biomarker of Diabetic Nephropathy
Completed NCT01935167 - To Determine the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy Phase 2
Recruiting NCT01673204 - Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Phase 4
Completed NCT01726816 - Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy Phase 2
Recruiting NCT01458158 - Matrix Metalloproteinases in Atherosclerosis of Chronic Kidney Disease N/A
Completed NCT01447147 - A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy Phase 2
Completed NCT01476501 - Vitamin D Supplementation in Diabetic Nephropathy Phase 2
Completed NCT01003236 - Evaluating the Renoprotective Effect of Milk Thistle Extract on Patients With Type II Diabetic Nephropathy Phase 2
Completed NCT00535925 - Nephropathy In Type 2 Diabetes and Cardio-renal Events Phase 4